Evidence map›Paper›PMID 34206873›Full record

ArticleJournal of personalized medicine2021

Schizophrenia-Like Behavioral Impairments in Mice with Suppressed Expression of Piccolo in the Medial Prefrontal Cortex.

Atsumi Nitta, Naotaka Izuo, Kohei Hamatani, Ryo Inagaki, Yuka Kusui, Kequan Fu, Takashi Asano, Youta Torii, Chikako Habuchi, Hirotaka Sekiguchi and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Atsumi NittaDepartment of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan.ORCID 0000-0001-6916-9160
Naotaka IzuoDepartment of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan.
Kohei HamataniDepartment of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan.
Ryo InagakiDepartment of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan.
Yuka KusuiDepartment of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan.
Kequan FuDepartment of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan.
Takashi AsanoDepartment of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan.
Youta ToriiDepartment of Psychiatry, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan.
Chikako HabuchiDepartment of Psychiatry, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan.
Hirotaka SekiguchiDepartment of Psychiatry, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan.
Shuji IritaniDepartment of Psychiatry, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan.
Shin-Ichi MuramatsuOpen Innovation Center, Division of Neurological Gene Therapy, Jichi Medical University, Shimotsuke 329-0498, Japan.ORCID 0000-0002-3185-7790
Norio OzakiDepartment of Psychiatry, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan.
Yoshiaki MiyamotoDepartment of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan.
University of Toyama · JPNagoya University · JPJichi Medical University · JPXuzhou Medical College · CN

Funding

Japan Agency for Medical Research and Development JP16mk0101076h0001, JP18dm0107087, JP18dk0307081, JP18dm0107108Japan Society for the Promotion of Science JP21H02632, 26293213Kobayashi International Scholarship Foundation noneSmoking Research Foundation none
6 · The paper itself

Abstract

Piccolo, a presynaptic cytomatrix protein, plays a role in synaptic vesicle trafficking in the presynaptic active zone. Certain single-nucleotide polymorphisms of the Piccolo-encoding gene

Indexed as

dorsal striatummedial prefrontal cortexoptogeneticspiccolopresynaptic cytomatrix proteinschizophrenia

Identifiers

PMID34206873
PMCPMC8304324
OpenAlexW3176552745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.